Member Info for JFK8

The only thing that you need to read here is the share price decimation , end of story

Is this the level the 10% brigade start buying in again

Testing 0.77p

Many years ago , probably ten I put 50 quid into a few companies , one of them being RRR . That 50 quid is now worth 36 pence lol

This one is Potent

Camonsertib (RP-3500) is owned and developed by Repare Therapeutics.

It was discovered and developed by Repare Therapeutics as part of their DNA-damage response oncology pipeline

In 2022, Repare licensed global development/commercial rights to Roche in a partnership deal

However, that deal was terminated in 2024, and Repare regained full global rights to camonsertib

Oh dear RRR down 9% now sub 0.0000000002

VR I want results from patients dosed

To be fair you might need to have a bit more patience seeing at the trial has only been going a few weeks and they have stated results will be in H2 , Remind me what the share price was 2 weeks ago , the SP has gone up everyday , the video has nothing to do with the price dropping today

That 200k buy was a sell , I did a dummy sell at the same time and got the same price

I think we might break past 80 today with some bigger 79p prints appearing and bid above VWAP

Safebreaker .. at least 15 of your last 20 posts have been replies to something Wyndrum has posted , just filter the clown and be done with it , unless of course you are one of his other usernames haha

The filter feature is a great tool , Please use it

The problem is when you have none to sell the price of it is irrelevant

Jesus , here we go again green boxes appearing , just ignore the Fudster and filter it

Christina Coughlin MD, PhD, CEO of Avacta, commented:

"Avacta continued to build momentum, having reached a number of important milestones in the first quarter of 2026, with treatment of the first patient in the FOCUS-01 trial of AVA6103 being a critical step forward in the development of our pre|CISION® platform. The sustained release mechanism allows the modulation of the kinetics of payload release, and also opens up the platform to many therapeutic modalities over the Gen One approach.

Furthermore, our AVA6000 (faridoxorubicin) program is especially well positioned following the updates from health authorities which allow the lifting of the lifetime maximum dosing and dose selection.

Our first, second and third generation assets are all attracting substantial interest from multiple parties for potential partnering. With our recent financing completed, we now have funding in place beyond multiple value inflection points through the rest of 2026 and we are excited about this potentially transformative period for the Company, delivering benefit for our patients and our shareholders alike."

Q1 business update

Hardly a leak with only 1% of shares traded and an 8% spread

Science day 5th of May

Typically Wynbore only turns up on red days

Bid 64 ask 67 , quoted 66 to sell 10k , no thanks Mm's

Advertised bid 63 , advertised ask 65 last bid trade price 63.355 last ask trade price 64.08 therefore actual spread 1.14%